Percutaneous transluminal balloon angioplasty (PTA) is a routine and widely accepted method for the treatment of peripheral arterial disease (1). However, its main limitation is late restenosis occurring at a 1-year rate of 6%–60%. Restenosis arises from injury to the arterial wall including overstretching, compression and rupture of the atherosclerotic plaque during balloon inflation. It is hypothesized that better long-term angioplasty results are observed if atherosclerotic plaques are removed rather than compressed and fractured. Laser angioplasty is one method to remove atherosclerotic plaques. We discuss the principles of lasers, physical properties of laser light, history of laser angioplasty and effects of laser radiation on tissues. Large clinical studies using laser angioplasty are critically assessed. In comparison to conventional PTA, there are some advantages of laser angioplasty: easier passage through chronic and calcified occlusions and according to some studies, better short- and medium-term results regarding limb salvage and management of in-stent restenoses. The main drawback of laser angioplasty is that current laser catheters are not able to create a sufficiently wide channel in the occlusion, meaning that adjunctive balloon dilatation is still required. Thus, long-term data may be misleading. Basic and applied research should continue to focus on enlargement of plaque ablation.

Principles of lasers
The term “laser” is an acronym of “light amplification by stimulated emission of radiation”. Lasers consist of an excitation source (pump) and an optical resonator (a cavity or a chamber), with mirrors at each end. The optical resonator contains an active medium.
The active medium defines the wavelength emitted by the laser, and gives the name to specific types of laser. This medium can be solid (e.g., neodymium yttrium aluminum garnet in Nd:YAG lasers, ruby crystal in ruby lasers), liquid (in dye lasers) or gas (argon ion in argon lasers, carbon dioxide in CO₂ lasers, and dimer of a halogen and inert gas in excimer lasers). The excitation source can be a flash lamp, electric current or another laser. When a certain quantum of energy is pumped from the source into the resonator, the atoms of the active medium become excited. After returning to their ground state, they release energy in the form of photons of light. This is called spontaneous emission of radiation, from which only a small amount of light energy is gained. Lasers work on the principle of stimulated emission of radiation, where photons within the optical resonator are reflected between mirrors and collide with atoms of the active medium, which causes them to reach an excited state. Much more light energy in the form of photons is gained from this method than by spontaneous emission. One of the mirrors of the optical resonator is partially transparent, allowing the photons to exit the cavity.

In contrast to nonlaser light, laser light has three unique characteristics: monochromaticity, coherence, and collimation. Monochromaticity is the emission of light of only one wavelength, or a narrow band of wavelengths. The coherence of laser light is based on stimulated emission, meaning that the light waves are parallel. Collimation can be defined as a narrow beam diameter with no divergence. Hence, laser light does not lose energy, even after covering a large distance.

Lasers can operate in either a continuous mode or in a pulsed mode, which generates short pulses (microsecond, nanosecond, or picosecond duration).

Lasers emit light with very high intensity. In medicine, they can be used for various applications, including cutting, coagulation and ablation of tissues, among others (6–8).

**Historical remarks**

In 1917, Einstein formulated a theory of stimulated emission of radiation (9). However, the first practical laser was not constructed until 1960, when Maiman demonstrated a laser with a ruby which was stimulated by a flash lamp. This laser emitted a deep red color with a wavelength of 694 nm in a pulsed mode (10).

In 1963, Mc Guff used a pulsed ruby laser for the experimental ablation of atherosclerotic plaques in postmortem human and canine specimens (11). A significant advance in laser angioplasty came in the 1980s, when optical fibers that could transmit laser radiation from the laser source into the artery were developed. In 1983, for the first time clinically, Ginsburg performed laser angioplasty in a patient with severe stenosis of the deep femoral artery and a threatened limb. He used an argon laser with an optical fiber, which was introduced into the inflated balloon catheter enabling coaxial positioning of the optical fiber (12).

In the same year, Fournial and Choy completed perioperative coronary laser angioplasty in 10 patients using an argon laser. This technique was used during by-pass surgery in five patients; the other five patients underwent laser therapy alone without bypass grafting. The results were not favorable, as 88% of the treated arteries occluded within three weeks (13). In 1985, a similar procedure was accomplished in the carotid arteries of two patients by Lammer and Choy (14).

At the beginning of laser angioplasty, continuous lasers were more commonly used. These lasers were taken from different fields of medicine where heat production was required, such as for tissue coagulation in surgery, for the management of bleeding ulcers in gastroenterology, and for treating retinal detachment in ophthalmology. For angioplasty, argon lasers and continuous Nd:YAG lasers were important during this period (6, 12–14). However, when ablating atherosclerotic plaques in the arteries, thermal interaction with the tissue is not desirable. This led to an era of intensive research and exploration of pulsed lasers due to their limited thermal effect, which will be discussed later. Initially, a pulsed Nd:YAG laser was used (15–19). The excimer laser (the term excimer is explained later in the text) was launched in clinical practice in the 1990s, when optical fibers for the transmission of radiation from the excimer laser became available (20–23). In USA, the Food and Drug Administration (FDA) has approved the use of excimer laser in patients with peripheral arterial disease only in 2003 (24).

**Laser-tissue interactions**

Laser radiation absorbed in a tissue has three mechanisms of action: (i) photothermal, (ii) photochemical, and (iii) acoustic mechanical (7).

**i) Photothermal effects**

Absorbed laser radiation is converted into thermal energy. Temperatures above 60°C lead to the denaturation of proteins and coagulation of the tissue. At temperatures over 100°C, exceeding the boiling point of intra- and extracellular water, vaporization occurs, causing tissue ablation. Photothermal effects are common for continuous lasers. In vivo, thermal injury can cause thrombosis and perforations of arteries. Therefore, continuous lasers are no longer utilized for angioplasty.

**ii) Photochemical effects**

Photochemical effects are nonthermal. They disintegrate tissues at the molecular level due to the breaking of molecular bonds and atom ionization. This can occur as a result of high energy photons of ultraviolet (UV) radiation from an excimer laser.

**iii) Acoustic mechanical**

Acoustic mechanical effects are also nonthermal. They arise from pulsed lasers, as
irradiation with short, high-energy pulses leads to the local formation of plasma, causing a shock wave. This shock wave induces limited tissue ablation with no thermal damage (6–8, 17, 20, 22).

At present, in peripheral and coronary laser angioplasty, only excimer lasers are used. Its name originates from a combination of “excited” and “dimer”. Its active lasing medium is a molecule consisting of a halogen and inert (rare, noble) gas (such as argon, krypton or xenon). Excimer lasers (“excimers”) are a very powerful source of UV energy, which are very well absorbed by tissue proteins and lipids. The mechanism of action of excimers is nonthermal (“cool lasers”), thus, they cause precise ablation of tissues without thermal damage. Depending on the composition of the lasing medium, emission of various wavelengths of UV light can be achieved, for example, 193 nm for argon fluoride (ArF), 249 nm for krypton fluoride (KrF) and 350 nm for xenon fluoride (XeF) (20–23).

For angioplasty, the most frequently used excimer is the xenon chloride (XeCl) excimer, which operates at a wavelength of 308 nm with relatively long pulses (pulse duration of 135 ns). The long pulse length is required for successful delivery of UV light by silica fiberoptics. Excimer laser energy is strongly absorbed by iodine contrast media and hemoglobin; therefore, a saline infusion must be administered while using the laser to replace blood and contrast (21–23).

Fig. 1 demonstrates thermal and nonthermal effects of two lasers on vascular tissue.

**Laser system**

For the application of lasers in the field of laser angioplasty, it is important to consider not only the laser itself, but also the whole laser system. This system consists of a laser, a connector, a laser catheter, and a catheter tip (Fig. 2).

The laser was discussed above. The connector acts as a guide to direct the laser light into the laser catheter. The laser catheter is composed of one or more optical fibers, which transmit the laser energy. The catheter tip is a very important component of the laser system, and may be crucial for the success of the laser procedure (25–27). Bare optical fibers were used when laser angioplasty procedures were first developed (12); however, they created only a narrow channel in the occlusion. In addition, the sharp ending of the fiber could perforate the artery, particularly in a tortuous vascular bed. Thus, several different catheter tips have been developed. Aside from their atraumatic shape, they allow the dispersion of radiation and create a wider channel during recanalization of an obstruction. It is worth mentioning the important roles of sapphire contact probes, tips, lens tips and metal contact probes (“hot tips”) in the history of laser angioplasty (15, 16, 19, 25–27).

For excimer laser angioplasty (ELA), a multifiber catheter is used. This catheter contains a bundle of concentrically arranged small optical fibers (50–100 µm in diameter) surrounding the central guide-wire lumen. At the end of the fibers is an optical shield. The optical shield is oriented to disperse radiation at the output from the catheter. Should the device work without an optical shield, only limited ablation of the occlusion is obtained, with no ablation between the fibers, a so-called “Swiss cheese effect”. The diameter of the broadest...
commercially available multifiber catheter is 2.5 mm (21–25).

The major limitation of current multifiber catheters lies in the fact that catheters cannot create a channel in an obstruction that is wider than the diameter of the catheter itself. Hence, laser angioplasty alone can only be performed in coronary arteries. In iliac and femoropopliteal arteries, the recanalized channel is not wide enough, and an additional balloon angioplasty is needed. This may distort long-term outcomes, in particular. To enable the use of multifiber catheters in femoropopliteal arteries, some modifications have been made to the multifiber catheter. One of these modified versions, the Turbo-Power catheter (Spectranetics), involves a guidewire lumen positioned eccentrically, and the catheter rotates around the guidewire by means of an external electric motor. In the Turbo-Tandem catheter (Spectranetics), the multifiber laser catheter is placed within a special guide catheter. The angled ramp at the tip of the guide catheter provides circumferential guidance and positioning of the laser catheter, allowing enlargement of the recanalized channel (21, 23, 28).

### Clinical studies

Randomized studies comparing the results of laser angioplasty using continuous wave lasers followed by PTA (“laser-assisted PTA”) to standard PTA alone for femoropopliteal occlusions did not show any significant differences in longer-term patency between the two methods (25–27).

Newer studies only use excimer lasers, referred to as ELA. Sometimes the term CLiRPATH (cool laser revascularization for peripheral artery therapy) is also used. In a study conducted by Scheinert et al. (29), 411 chronic occlusions of the superficial femoral artery, with an average length of 19.4±6 cm, were managed using ELA with adjunctive PTA or stenting. The technical success rate was reported to be 90.5%. Complications included acute reocclusion (1.0%), perforation (2.2%), and distal embolization (3.9%). However, the primary patency was only 33.6% at 1 year. The 1-year primary-assisted and secondary patency rates were 65.1% and 75.9%, respectively.

Steinkamp et al. (30) published a study involving 215 patients with popliteal artery occlusion, with an average length of 10.4 cm. This prospective nonrandomized study compared ELA with subsequent PTA (127 patients) with PTA alone (88 patients). After a mean follow-up of 36 months (range, 6–52 months) the primary and secondary patency rates were 21.7% and 50.8%, respectively, in patients who underwent ELA plus PTA, and 16.3% and 35.2%, respectively, in the PTA group. No statistically significant differences were found between groups.

The multicenter prospective registry CELLO (CLiRPATH excimer laser system to enlarge lumen openings) included 65 patients; 52 patients with femoropopliteal stenosis >70% and 13 patients with femoropopliteal occlusion. The primary endpoint was a reduction in the diameter of the stenosis, measured by ultrasound following laser ablation using a Turbo-Tandem catheter prior to any adjunctive therapy. At baseline (before ELA), the stenosis was 77%±15%, which was reduced to 34.7%±17.8% after ELA. Adjunctive PTA was performed in 64.6%, PTA and stenting performed in 23.1%. Of the patients in the trial, 12.3% did not receive any subsequent treatment. Patency rates (restenosis <50%) were 59% and 54% at 6 and 12 months, respectively (31).

In the prospective multicenter LACI (laser angioplasty for critical limb ischemia) study, 155 limbs at high risk for amputation were treated. The patients were poor candidates for surgery due to cardiorespiratory comorbidities. In total, 426 femoropopliteal and infrapopliteal lesions were intervened. After ELA, PTA was performed in all cases, and a stent was implanted in 45% of limbs. In 8%, it was not possible to cross the lesion with the guidewire, so a combination of laser radiation and shifting of the guidewire had to be carried out (“step by step” technique, described below). Procedural success, defined as <50% residual stenosis in all treated lesions, was accomplished in 86% of limbs. At 6 months follow-up, limb salvage was achieved in 92% (32). Favorable outcomes concerning limb salvage using ELA and PTA were confirmed by the Belgian version of the LACI study, in which 51 critically ischemic limbs were intervened with a salvage rate of 90.5% at 6 months (33).

The EXCITE ISR (excimer laser randomized controlled study for treatment of femoropopliteal in-stent restenosis) was the first large, prospective, randomized multicenter study comparing ELA plus PTA and PTA alone. It analyzed 250 patients with femoropopliteal in-stent restenosis. Patients were enrolled and randomly divided into two groups, ELA plus PTA and PTA alone, in a 2:1 ratio. The mean lesion lengths were 19.6±12.0 cm and 19.3±11.9 cm in the ELA plus PTA and PTA groups, respectively. The ELA plus PTA group demonstrated a superior and significant procedural success rate of 93.5% versus 82.7% obtained for PTA alone (P = 0.01), with significantly fewer procedural complications. The 6-month freedom from target lesion revascularization (TLR) was significantly higher in the ELA plus PTA group at 73.5% compared with 51.8% for the PTA group (P < 0.005), and 30-day major adverse event rates were 5.8% versus 20.5% (P < 0.001), respectively. ELA plus PTA was associated with a 52% reduction in TLR (hazard ratio, 0.48; 95% confidence interval, 0.31–0.74) (34).

### Conclusion

In order to critically assess the impact of peripheral laser angioplasty in the percutaneous treatment of peripheral arterial disease, its benefits and drawbacks must be discussed.
The benefits of peripheral laser angioplasty are listed below:

Laser angioplasty is a safe method, as the complication rate does not exceed that of standard PTA. Perforation of the arteries in ELA is relatively rare, only occurring in up to 2.2% of cases (29, 32). Distal embolization ranges from 2.5% to 9% in larger studies (34–36).

An advantage of laser angioplasty is easier passage through chronic and calcified occlusions. According to the literature, crossing such obstructions with a conventional guidewire may fail in 8%–34% of all occlusions (32, 37). In ELA, a “step by step” technique is often used in these cases, whereby laser radiation is applied simultaneously with shifting of the guidewire in the occlusion. Laser catheters with a central lumen for a guidewire advance are also more likely endoluminally than subintimally (22, 38).

In patients with critical limb ischemia, some larger studies have reported positive results for avoiding amputation by means of the ELA plus PTA technique (32, 33). However, these studies were not randomized to standard PTA or stenting, and the follow-up period was relatively short (6 months).

Regarding femoropopliteal in-stent restenoses, a randomized study and meta-analysis found out better short- and medium-term outcomes for ELA plus PTA than for PTA alone (34, 39).

The drawbacks of peripheral laser angioplasty are listed below:

Current multifiber laser catheters (even their novel modifications) cannot create a wide enough channel in the occluded artery, which requires subsequent balloon dilatation. Hence, long-term data for laser angioplasty may be influenced by adjunctive balloon dilatation (21, 23, 28, 29–34).

Peripheral laser angioplasty has a higher cost when compared with plain PTA/stenting (38).

Table highlights the benefits and drawbacks of excimer laser angioplasty.

Despite the abovementioned shortcomings, laser angioplasty represents an appealing concept for angioplasty, as it facilitates the removal of atherosclerotic plaques, which may be important for preventing restenosis/reocclusion after angioplasty. In our opinion, basic and applied research should continue, mainly with respect to enlargement of plaque ablation.

We also believe that laser equipment should be present in larger angioplasty centers with the aim to provide complex percutaneous management of peripheral arterial disease.

Conflict of interest disclosure

The author declared no conflicts of interest.

References

1. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG. Inter-society consensus for management of peripheral arterial disease (TASC II). J Vasc Surg 2007; 45 (Suppl S):5–67. [CrossRef]